Global Liver Cancer Diagnostics Market Analysis, Size, Share, Growth, Trends, and Forecast Report 2022

Fact.MR Fact.MR

Dublin 2, Ireland, 2018-Feb-14 — /EPR Network/ — Medical organizations as well as leaders in the global pharmaceuticals industry are stepping up their efforts towards development of profound diagnosis for liver cancer. Rising number of deaths caused by liver cancer is taking a toll on governments as people are demanding precision diagnosis and a cure-all for this terminal disease. In a bid to adapt to the urban rat race, millions of consumers have adopted lifestyles that are stemming the occurrence of liver cancer. For public administration authorities, compelling people to avoid such lifestyles is like challenging the status quo. The burden of controlling the incidence of liver cancer gets passed on to hospitals & medical research organizations as they strive to develop novel diagnostic and therapeutic procedures.

The global market for liver cancer diagnostics is anticipated to witness significant impact from diagnosis-associated patient compliance trials. Positive attitudes of patients towards certain diagnosis alternatives is decisive in changing future undertakings. Prominent diagnostic tools are likely to be replaced with their upgraded variants. The report has highlighted the influence of government undertakings in offering a better compliance for diagnosis of liver cancer patients.

Request Free Sample Report-

Takeaways from the Global Liver Cancer Diagnostics Market

1.    In terms of revenues, North America will remain the most lucrative region in the global market for liver cancer diagnostics. In addition, liver cancer diagnostics markets in North America and Europe will exhibit expansion at similar CAGRs through 2022.

2.    Liver cancer diagnostics markets in Japan and MEA will exhibit a sluggish growth during the forecast period.

3.    Biopsy tests will continue to exhibit the highest CAGR through 2022, among test type in the global market, followed by LFTs.

4.    AFP test is projected to remain sought-after for liver cancer diagnostics over the forecast period. Revenues from AFP tests are estimated to hold more than half market share in 2017, and are expected to attain 52 BPS in their market share by 2022-end.

5.    Hospital-associated labs are expected to remain sought-after in the market for liver cancer diagnostics. Liver cancer diagnostics in the hospital-associated labs are expected to account for largest revenues during the forecast period.

6.    Independent diagnostic laboratories will continue to be the second most lucrative segment among end-users in the global market for liver cancer diagnostics.

7.    Diagnosis of liver cancer in cancer research institutes will continue to register the highest CAGR over the forecast period.

Browse Full Report with TOC-

North America to Remain Dominant in the Global Liver Cancer Diagnostics Market

North America is expected to remain dominant in the global liver cancer diagnostics market, in terms of revenues. In addition, the markets for liver cancer diagnostics in North America and Europe are estimated to exhibit a parallel expansion at 5.6% CAGR through 2022. In contrast, markets in Japan and MEA are expected to exhibit a sluggish expansion during the forecast period.

Based on test type, biopsy test segment is expected to register the highest CAGR in the market through 2022, followed by LFTs. AFP test is estimated to remain preferred for liver cancer diagnostics in the global market. Revenue from AFP test is expected to account for over half share of the market in 2017, and is estimated to gain 52 BPS in its market share between 2017 and 2022.

Hospital-associated Labs to Remain Sought-after for Liver Cancer Diagnostics

Hospital-associated labs will continue to be sought-after for liver cancer diagnostics across the globe. Liver cancer diagnostics in hospital-associated labs will account for the largest revenues by 2022-end. Independent diagnostic laboratories will remain the second most lucrative end-users in the global liver cancer diagnostics market. In addition, liver cancer diagnostics in cancer research institutes are expected to register the fastest expansion over the forecast period.

Competition Tracking

The report has also profiled leading players in the global liver cancer diagnostics market, which include Illumina, Inc., Foundation Medicine, Inc., Danaher Corporation
Sysmex Corporation, and Biocept, Inc.

Check Discount-

About Fact.MR
Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized  Healthcare market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that’s why we publish multi-industry global, regional, and country-specific research reports.

Contact Us
Suite 9884
27 Upper Pembroke Street,
Dublin 2, Ireland
Telephone: +353-1-6111-593

Matched content

Editor’s pick

Express Press Release Distribution